Allylescaline Stats & Data

Allylescaline was first documented in the scientific literature by Czech chemist Otakar Leminger in 1972. The compound received broader attention when American chemist Alexander Shulgin synthesized and characterized its psychoactive effects, publishing his findings in the 1991 book PiHKAL: A Chemical Love Story. In PiHKAL, Shulgin described allylescaline's subjective effects and established dosage parameters based on his bioassay methodology. The compound remained relatively obscure for over two decades following PiHKAL's publication. It emerged on the research chemical market in 2013, when it was identified as a novel designer drug being sold online. This appearance prompted regulatory responses in several countries during the mid-2010s.

Forked from Subjective Effect Documentation work by Josie Kins, August 2016. Via dose.wiki (CC0).

The toxicity and long-term health effects of recreational allylescaline use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because allylescaline is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried allylescaline suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption. It is strongly recommended that one use harm reduction practices when using this drug.

Effects aggregated from 8 experience reports (8 single-substance Erowid)

Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

Too few reports for bars: these effects come from 8 single-substance Erowid reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

Dose distribution from experience reports, one dose per report (the first listed). Values above Q3 + 3×IQR are left out as outliers.

From 33 individual dose entries. Values above Q3 + 3×IQR are left out as outliers.

Most co-occurring substances, as a share of all 20 reports filed under Allylescaline; whiskers are 95% intervals

Most common forms and preparations, as a share of the 15 reports that give one

Too few reports for bars: these forms come from 15 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

• Powder / Crystals 7 of 15
• Capsule 6 of 15
• Liquid 2 of 15

Dose per kg of body weight, one dose per report (the first listed), from reports giving a weight of 30–250 kg. Values above Q3 + 3×IQR are left out as outliers.

Redosing behavior across 15 reports